Wave Life Sciences, Inc.

What they do

Wave Life Sciences uses its PRISM platform to design RNA medicines, including RNAi (SpiNA) and RNA editing (AIMers) modalities. Its lead programs target INHBE for obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 liver disease (WVE-008), with additional clinical programs for Duchenne muscular dystrophy and Huntington's disease. The company has no approved products and generates revenue primarily from collaborations and grants.

Revenue drivers

• Collaboration revenue — Revenue is primarily from partnerships; annual revenue fell to $42.7M in 2025 from $108.3M in 2024, indicating declining collaboration income.
• Grants and other revenue — Limited contribution; quarterly revenue was $2.3M in Q2 2026, reflecting minimal non-collaboration sources.
• Licensing and milestone payments — Potential future payments from partners, but no specific current amounts disclosed.

Recent performance

For Q2 2026, Wave reported revenue of $2.3M, down sharply from $38.2M in Q1 2026, which likely included one-time collaboration payments. The company had $490.6M in cash and marketable securities as of June 30, 2026, providing runway into 3Q 2028. Net losses have widened, with 2025 net loss of $204.4M versus $97.0M in 2024. Operating cash flow was negative $187.5M in 2025.

Strategy

Wave is prioritizing three GalNAc-conjugated hepatic/metabolic programs: WVE-007 for obesity, WVE-006 for AATD, and WVE-008 for PNPLA3 liver disease. The company is advancing WVE-007 into Phase 2 trials, including combination and maintenance studies with incretins. It seeks regulatory pathways for WVE-006 (FDA meeting for potential accelerated approval) and plans to submit a CTA for WVE-008 in 2H 2026. Management emphasizes its proprietary chemistry and multimodal RNA platform as key differentiators.

Risks

• Clinical-stage dependence — No approved products; all candidates are in clinical trials, with high risk of failure.
• Cash burn and funding needs — Negative cash flow of $187.5M in 2025; despite $490.6M cash, future funding may be required before profitability.
• Collaboration revenue volatility — Revenue dropped sharply from $108.3M in 2024 to $42.7M in 2025, showing dependence on sporadic partnership payments.
• Regulatory and competitive uncertainty — FDA discussions for WVE-006 are at early stage, and obesity market competition from incretins is intense.

Outlook

Management expects to initiate Phase 2 combination and post-incretin maintenance trials for WVE-007 in 2H 2026, and to report additional Phase 1 data including the 600 mg cohort in 2H 2026. They plan a CTA submission for WVE-008 in 2H 2026 and an FDA meeting on WVE-006's accelerated approval pathway by end of summer 2026. The company expects to be funded into 3Q 2028.